Provisional end result of the public tender offer of Samsung Biologics Co., Ltd.
Ad hoc announcements pursuant to Art. 53 LR
Baar, Switzerland, 2 November 2026 – Samsung Biologics Co., Ltd. (“Samsung Biologics”), through its direct subsidiary Samsung Peptide AG (“Samsung Peptide”), today published the provisional end result of its public tender offer (the “Offer”) for all publicly held registered shares of PolyPeptide Group AG (“PolyPeptide”) (SIX: PPGN).
[…]